Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1 in a Rat Parkinson’s Disease Model

Masanori ITAKURA; Tomoko KOHDA; Takeya KUBO; Yuko SEMI; Kazuhiro NISHIYAMA; Yasu-Taka AZUMA; Hidemitsu NAKAJIMA; Shunji KOZAKI; Tadayoshi TAKEUCHI

doi:10.1292/jvms.14-0184

Pharmacology

Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1 in a Rat Parkinson’s Disease Model

Masanori ITAKURA, Tomoko KOHDA, Takeya KUBO, Yuko SEMI, Kazuhiro NISHIYAMA, Yasu-Taka AZUMA, Hidemitsu NAKAJIMA, Shunji KOZAKI, Tadayoshi TAKEUCHI

著者情報

Masanori ITAKURA
Laboratory of Veterinary Pharmacology, Graduate School of Life and Environmental Science, Osaka Prefecture University, 1–58 Rinku Ourai Kita, Izumisano-shi, Osaka 598–8531, Japan
Tomoko KOHDA
Laboratory of Veterinary Epidemiology, Graduate School of Life and Environmental Science, Osaka Prefecture University, 1–58 Rinku Ourai Kita, Izumisano-shi, Osaka 598–8531, Japan
Takeya KUBO
Laboratory of Veterinary Pharmacology, Graduate School of Life and Environmental Science, Osaka Prefecture University, 1–58 Rinku Ourai Kita, Izumisano-shi, Osaka 598–8531, Japan
Yuko SEMI
Laboratory of Veterinary Pharmacology, Graduate School of Life and Environmental Science, Osaka Prefecture University, 1–58 Rinku Ourai Kita, Izumisano-shi, Osaka 598–8531, Japan
Kazuhiro NISHIYAMA
Laboratory of Veterinary Pharmacology, Graduate School of Life and Environmental Science, Osaka Prefecture University, 1–58 Rinku Ourai Kita, Izumisano-shi, Osaka 598–8531, Japan
Yasu-Taka AZUMA
Laboratory of Veterinary Pharmacology, Graduate School of Life and Environmental Science, Osaka Prefecture University, 1–58 Rinku Ourai Kita, Izumisano-shi, Osaka 598–8531, Japan
Hidemitsu NAKAJIMA
Laboratory of Veterinary Pharmacology, Graduate School of Life and Environmental Science, Osaka Prefecture University, 1–58 Rinku Ourai Kita, Izumisano-shi, Osaka 598–8531, Japan
Shunji KOZAKI
Laboratory of Veterinary Epidemiology, Graduate School of Life and Environmental Science, Osaka Prefecture University, 1–58 Rinku Ourai Kita, Izumisano-shi, Osaka 598–8531, Japan
Tadayoshi TAKEUCHI
Laboratory of Veterinary Pharmacology, Graduate School of Life and Environmental Science, Osaka Prefecture University, 1–58 Rinku Ourai Kita, Izumisano-shi, Osaka 598–8531, Japan

キーワード: adverse effect, botulinum neurotoxin, Parkinson’s disease, rat, subtype

ジャーナルフリー

2014 年 76 巻 8 号 p. 1189-1193

DOI https://doi.org/10.1292/jvms.14-0184

Browse “Advance online publication” version

詳細

抄録

Botulinum neurotoxin type A (BoNT/A) cleaves SNAP-25 and interrupts the release of acetylcholine. We previously reported that BoNT/A subtype 2 (BoNT/A2) ameliorates pathologic behavior more effectively than subtype 1 (BoNT/A1) in a rat Parkinson’s disease model. Here, we further show BoNT/A2 has fewer adverse effects than BoNT/A1. We first confirmed that intrastriatal treatments of both BoNT/As had no-effect on dopaminergic terminals in the striatum. SNAP-25 cleaved by BoNT/A2 was strictly localized to the striatum on the injected side; however, SNAP-25 cleaved by BoNT/A1 diffused contralaterally. Furthermore, treatment with BoNT/A1 caused a significant reduction in body weight, while BoNT/A2 treatment did not. These results suggest that BoNT/A2 is more beneficial for clinical application against Parkinson’s disease than BoNT/A1.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）